{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T23:56:30Z","timestamp":1764201390998,"version":"3.46.0"},"reference-count":15,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nuklearmedizin"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In 2018, the Food and Drug Administration (FDA) approved lutetium-177 (177Lu) DOTATATE (LUTATHERA, Advanced Accelerator Applications [Novartis]) for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Since then, 177Lu DOTATATE has been increasingly used as a treatment option for NETs. Less than 5 years later, in March 2022, 177Lu vipivotide tetraxetan (PLUVICTO, Advanced Accelerator Applications) received FDA approval for the treatment of prostatespecific membrane antigen-positive castration-resistant metastatic prostate cancer. Both drugs are excellent examples of viable radiotheranostic therapies. As more radiotheranostic agents and applications get adopted in clinical practice, interventional radiologists are likely to get exposed to this field in a way or another. In this article, we discuss the fundamentals of radiotheranostic therapy and explore the expanding role interventional radiology (IR) is expected to play as an essential partner in modern oncology practice.<\/jats:p>","DOI":"10.1055\/a-2729-8686","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T23:52:11Z","timestamp":1764201131000},"page":"352-355","source":"Crossref","is-referenced-by-count":0,"title":["Interventional Radiology in the Era of Radiotheranostics: An Update for Interventional Radiologists!"],"prefix":"10.1055","volume":"64","author":[{"given":"Islam A.S.","family":"Elhelf","sequence":"additional","affiliation":[{"name":"Interventional Radiology, Department of Radiology, Medical College of Georgia, Augusta University, Augusta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Clemenshaw","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, Department of Radiology, Medical College of Georgia, Augusta University, Augusta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40658-017-0182-7","article-title":"Saul Hertz, MD, and the birth of radionuclide therapy","volume":"4","author":"F H Fahey","year":"2017","journal-title":"EJNMMI Phys"},{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1053\/j.semnuclmed.2019.07.006","article-title":"Targeted radionuclide therapy: a historical and personal review","volume":"50","author":"S J Goldsmith","year":"2020","journal-title":"Semin Nucl Med"},{"issue":"03","key":"ref3","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1016\/S1470-2045(19)30821-6","article-title":"Radiotheranostics: a roadmap for future development","volume":"21","author":"K Herrmann","year":"2020","journal-title":"Lancet Oncol"},{"issue":"03","key":"ref4","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3390\/ph12030114","article-title":"Lutathera: the first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy","volume":"12","author":"U Hennrich","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"issue":"07","key":"ref5","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2967\/jnumed.118.230607","article-title":"NANETS\/SNMMI procedure standard for somatostatin receptor-based peptide receptor radionuclide therapy with 177Lu-DOTATATE","volume":"60","author":"T A Hope","year":"2019","journal-title":"J Nucl Med"},{"issue":"09","key":"ref6","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.2967\/jnumed.118.223016","article-title":"111In-pentetreotide scintigraphy versus 68Ga-DOTATATE PET: impact on Krenning scores and effect of tumor burden","volume":"60","author":"T A Hope","year":"2019","journal-title":"J Nucl Med"},{"issue":"01","key":"ref7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2011-300831","article-title":"Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)","volume":"61","author":"J K Ramage","year":"2012","journal-title":"Gut"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.2967\/jnumed.121.263041","article-title":"Radioembolization versus bland or chemoembolization for liver-dominant neuroendocrine tumors: Is it an either\/or question?","volume":"62","author":"J R Strosberg","year":"2021","journal-title":"J Nucl Med"},{"issue":"15","key":"ref9","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.3748\/wjg.v23.i15.2640","article-title":"Is there still a role for the hepatic locoregional treatment of metastatic neuroendocrine tumors in the era of systemic targeted therapies?","volume":"23","author":"F Cavalcoli","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"02","key":"ref10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"J Strosberg","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"ref11","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1097\/RLU.0000000000001846","article-title":"Effective prostate-specific membrane antigen-based 18F-DCFPyL-guided cryoablation of a single positive site in a patient believed to be more metastatic on 11C-choline PET\/CT","volume":"42","author":"F H Cornelis","year":"2017","journal-title":"Clin Nucl Med"},{"issue":"04","key":"ref12","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.eururo.2018.11.050","article-title":"Can local ablative radiotherapy revert castration-resistant prostate cancer to an earlier stage of disease?","volume":"75","author":"F Lohaus","year":"2019","journal-title":"Eur Urol"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13063-019-3888-0","article-title":"Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial)","volume":"21","author":"S C Ebbers","year":"2020","journal-title":"Trials"},{"issue":"03","key":"ref14","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jvir.2021.10.016","article-title":"Selective intra-arterial lutetium-177-labeled prostate-specific membrane antigen therapy for castration-resistant prostate cancer: initial results","volume":"33","author":"H B Sayman","year":"2022","journal-title":"J Vasc Interv Radiol"},{"issue":"03","key":"ref15","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2967\/jnumed.121.262491","article-title":"Intraarterial administration boosts 177Lu-HA-DOTATATE accumulation in salvage meningioma patients","volume":"63","author":"E PA Vonken","year":"2022","journal-title":"J Nucl Med"}],"container-title":["Nuklearmedizin - NuclearMedicine"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2729-8686.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T23:52:19Z","timestamp":1764201139000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2729-8686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":15,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2025,11,26]]},"published-print":{"date-parts":[[2025,12]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2729-8686","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0029-5566","2567-6407"],"issn-type":[{"value":"0029-5566","type":"print"},{"value":"2567-6407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]}}}